8-K: Cognition Therapeutics Announces Positive Phase 2 Trial Results for Alzheimer's Drug CT1812

Cognition Therapeutics' CT1812 shows promising results in a Phase 2 trial, demonstrating a slowing of cognitive decline in patients with mild-to-moderate Alzheimer's disease.

Summary

• Cognition Therapeutics has released results from its Phase 2 SHINE trial of CT1812, an oral drug for mild-to-moderate Alzheimer's disease.
• The trial showed that CT1812 slowed cognitive decline, with a 39% reduction in the rate of decline on the ADAS-Cog 11 scale at six months compared to placebo.
• Both 100mg and 300mg doses of CT1812 showed similar efficacy, with the 100mg dose having a better safety profile.
• The drug also showed a reduction in neurofilament light chain (NfL) in cerebrospinal fluid, suggesting a potential slowing of neurodegeneration.
• The study was partially funded by a $31 million grant from the National Institute on Aging (NIA).

Sentiment

Score: 7

Explanation: The document presents positive results from a Phase 2 trial, with a clear signal of efficacy and a favorable safety profile. However, the lack of statistical significance on the primary endpoint and the need for further trials temper the overall optimism.

Positives

• CT1812 demonstrated a favorable safety and tolerability profile, with most adverse events being mild or moderate.
• The 100mg dose of CT1812 showed comparable efficacy to the 300mg dose, but with no discontinuations due to adverse events.
• The study showed a consistent efficacy signal across multiple cognitive endpoints.
• The reduction in NfL levels suggests a potential impact on neurodegeneration, which is a key aspect of Alzheimer's disease.
• The oral, once-daily administration of CT1812 could be a significant advantage for patients.

Negatives

• The 300mg dose of CT1812 had a higher rate of discontinuations due to elevated liver enzymes.
• While the results were directionally favorable, the primary endpoint of ADAS-Cog 11 at day 182 did not reach statistical significance.
• Some cognitive and functional measures showed consistent but not statistically significant results, suggesting a need for longer-term trials.

Risks

• The forward-looking statements in the presentation are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's ability to advance product candidates through development activities, preclinical studies, and clinical trials is subject to risks.
• The timing, scope, and likelihood of regulatory filings and approvals are uncertain.
• The company faces competition and needs to secure new grant funding.
• The company's estimates of expenses and profitability are subject to change.

Future Outlook

The company plans to use the results of the SHINE trial to inform the dosing for the next phase of study. They are also continuing with other trials including the START trial in early Alzheimers and a trial in geographic atrophy.

Management Comments

• Lisa Ricciardi, President and CEO, is listed as the signatory of the report.
• The presentation includes remarks from Dr. Martin Sadowski, a study investigator and industry thought leader.

Industry Context

The results are significant in the context of the ongoing search for effective Alzheimer's treatments, particularly those targeting amyloid oligomers. The company is positioning CT1812 as a potential alternative to existing therapies that target amyloid plaques.

Comparison to Industry Standards

• The magnitude of effect observed with CT1812, a 39% slowing of cognitive decline on the ADAS-Cog 11 scale, is comparable to that of approved monoclonal antibody (MAb) treatments for Alzheimer's disease, such as Aduhelm and Leqembi.
• The reduction in neurofilament light chain (NfL) in cerebrospinal fluid is a positive sign, as it suggests a potential slowing of neurodegeneration, a key aspect of Alzheimer's disease, similar to what has been observed with other experimental therapeutics.
• The safety profile of CT1812, particularly at the 100mg dose, appears favorable compared to some other Alzheimer's treatments that have shown higher rates of adverse events.

Stakeholder Impact

• The positive results could be beneficial for shareholders, potentially increasing the company's value.
• The results offer hope for patients with Alzheimer's disease and their families.
• The company's employees may be positively impacted by the progress of the drug development.
• The results could strengthen the company's relationships with its funding partners.

Next Steps

• The company will use the results to inform dosing for the next phase of study.
• The company is continuing with other trials including the START trial in early Alzheimers and a trial in geographic atrophy.

Key Dates

Keywords

Alzheimer's disease, CT1812, Cognition Therapeutics, clinical trial, neurodegeneration, amyloid oligomers, cognitive decline, ADAS-Cog 11, NfL, biomarkers